TITLE

Severe Restrictions for Avandia in U.S. E.U

PUB. DATE
October 2010
SOURCE
Pharmaceutical Representative;Oct2010, Vol. 40 Issue 10, p8
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the recall of GlaxoSmithKline's Avandia from the European Union (EU) market and is facing restrictions in the U.S. due to the product's adverse effects during and after treatment.
ACCESSION #
54427745

 

Related Articles

  • GSK: Senate Avandia Report Erroneous.  // BioWorld Today;2/26/2010, Vol. 21 Issue 38, p4 

    The article reports on the defense of GlaxoSmithKline plc (GSK) regarding allegations that the pharmaceutical company did not warn the public about the cardiovascular risks of Avandia (rosiglitazone), a drug used for curing diabetes.

  • GSK braces for £2.2b legal charge.  // TCE: The Chemical Engineer;Feb2011, Issue 836, p10 

    The article reports that pharmaceutical firm Glaxosmithkline has allotted 2.2 billion British pounds to settle legal claims relating to its type II diabetes medication Avandia.

  • Rosiglitazone: accusations over cardiovascular safety.  // Reactions Weekly;2/27/2010, Issue 1290, p2 

    The article reports on an accusation from the U.S. Senate Committee on Finance that GlaxoSmithKline has covered up safety concerns after conducting an enquiry into Avandia or rosiglitazone.

  • Restrictions Pulled on GSK's Avandia.  // Chain Drug Review;12/16/2013, Vol. 35 Issue 20, p103 

    The article focuses on the removal of restrictions on the use of GlaxoSmithKline PLC's diabetic medicine Avandia by the U.S. Food and Drug Administration.

  • GSK refuses to pay pharmacists for recall. Cameron, Amanda // New Zealand Doctor;2/29/2012, p12 

    The article reports that GlaxoSmithKline (GSK) will not pay community physicians who were affected by the recall of Marevan tablets in January 2010.

  • Marevan recalled.  // New Zealand Doctor;2/10/2010, p4 

    The article reports on a product recall conducted by GlaxoSmithKline in 2010 due to its uncertainty on the amount of warfarin contained in its Marevan three-milligram tablets.

  • Emo-Cort 2.5% lotion recalled because of mould contamination.  // Reactions Weekly;11/6/2010, Issue 1326, p7 

    The article reports on the voluntary recall by GlaxoSmithKline of Emo-Cort 2.5% lotion, lot 5R6, because of mould contamination.

  • CLINICAL CORNER. Bhatt, Deepak // Medical Marketing & Media;Mar2014, Vol. 49 Issue 3, p44 

    The article focuses on the safety issues on drugs to treat diabetes including the findings of a study that Salsate, a drug for arthritis, can lower blood glucose, trials for Avandia (rosiglitazone) from GlaxoSmithKline (GSK), and health risks presented by Onglyza (Saxagliptin) from AstraZeneca PLC.

  • A spoonful of sugar? Mills, Dale // Green Left Weekly;7/28/2010, Issue 846, p6 

    In this article the author discusses the availability of Avandia in the U.S., a diabetes medication manufactured by GlaxoSmithKline despite its potential to cause heart attacks and strokes in patients, and argues that the continued availability needs to be balanced.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics